Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share for 2Q25, indicating improved financial performance relative to estimates. Additionally, the clinical trials for OKI-219 showed positive safety profiles, with the treatment being well-tolerated and no significant adverse events reported, which bodes well for future development. The combination of reduced losses and promising clinical results underpins a positive outlook for the company as it continues to advance its precision medicine initiatives in the cancer treatment space.

Bears say

OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share for the full year 2025, which reflects a slight improvement from a prior estimate of $4.75 per share. The company faces several significant risks, including the potential for negative clinical results associated with its lead asset, OKI-219, and possible delays in advancing its pipeline candidates to regulatory approval stages. Additionally, competitive pressures from other mutant-selective PI3Kα inhibitors and the risk of long-term shareholder dilution contribute to a challenging outlook for the company's financial stability.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.